CJC-1131 ConjuChem

Current Opinion in Investigational Drugs

Volumn 4, Issue 10, 2003, Pages 1245-1249

  Giannoukakis, Nick ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANTIDIABETIC AGENT; CJC 1131; EXENDIN 4; EXENDIN 4 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; LIRAGLUTIDE; METOCLOPRAMIDE; SULFONYLUREA; UNCLASSIFIED DRUG; ZP 10;

AREA UNDER THE CURVE; BINDING AFFINITY; CLINICAL TRIAL; DOSE RESPONSE; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TOXICITY; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; HUMAN; IMMUNOGENICITY; INJECTION SITE; INSULIN HYPOGLYCEMIA; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; REVIEW; SIDE EFFECT; SKIN IRRITATION; STEADY STATE; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; VOMITING; WEIGHT REDUCTION;

CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; HUMANS; HYPOGLYCEMIC AGENTS; MALEIMIDES; PEPTIDES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0242490138     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 233314 Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Kieffer TJ, McIntosh CH, Pederson RA Endocrinology 1995 136 8 3585-3596
2. 233337 Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ Dig Dis Sci 1993 38 4 665-673
3. 240408 Serum albumin. Peters T Jr Adv Protein Chem 1985 37 161-245
4. 306810 A role for glucagon-like peptide-1 in the central regulation of feeding. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, Health MM, Lambert PD, Wilding JP et al. Nature 1996 379 6560 69-72
5. 306812 Glucagon-like peptides. Drucker DJ Diabetes 1998 47 2 159-169
6. 362275 Glucagon-like peptide 1 (GLP-1): An intestinal hormone, signalling nutritional abundance, with an unusual therapeutic potential. Holst JJ Trends Endocrinol Metab 1999 10 229-235
7. 374863 Product pipeline. Conjuchem Inc Company World Wide Web Site 2000 July 18
8. 410194 ConjuChem Inc announces preclinical progression of its DAC:GLP-1 compound for type II diabetes. ConjuChem Inc Press Release 2001 May 23
9. 439496 Development of glucagon-like peptide-1-based pharmaceuticals as therapeutic agents for the treatment of diabetes. Ducker DJ Curr Pharm Design 2001 7 14 1399-1412
10. 454061 CJC-1131, the novel long acting GLP-1 analogue, delays gastric emptying and demonstrates safety and tolerability in preclinical testing. Lawrence B, Wen SY, Jette L, Thibadeau K, Castaigne JP Diabetes 2002 51 2 A340-OR
11. 454095 The long-acting GLP-1 agonist CJC-1131 exhibits high potency and extended pharmacokinetics in vivo. Bridon DP, Thibaudeau K, Archeveque BP, Pham H, Robitaille MF, Drucker DJ, Leger R, Castaigne JP Diabetes 2002 51 2 A378-P
12. 454256 Development and characterization of long-acting degradation resistant GLP-1-DAC compounds for the treatment of type 2 diabetes. Thibaudeau K, Smith DC, Jette L, Castaigne JP, Bridon DP, Kim JG, Baggio LL, Drucker DJ Diabetes 2002 51 2 A471-P
13. 454479 The GLP-1-DAC analogue CJC-1131 upregulates insulin gene expression and exerts a memory effect on glycemic control in db/db mice. Kim JG, Baggio LL, Drucker DJ Diabetes 2000 51 2 A1391-P
14. 457323 ConjuChem announces start of phase I trial for DAC:GLP-1, a type II diabetes drug candidate. ConjuChem Inc Press Release 2002 July 08
15. 466084 ConjuChem updates status of phase I trial for diabetes drug candidate. ConjuChem Inc Press Release October 07
16. 478018 Novel peptides under development for the treatment of type 1 and type 2 diabetes mellitus. Baron AD, Kim D, Weyer C Curr Drug Targets Immune Endocr Metabol Disord 2002 2 63-82
17. 478025 Insulinotropic actions of exendin-4 and glucagon-like peptide-1 in vivo and in vitro. Parkes DG, Pittner R, Jodka C, Smith P, Young A Metabolism 2001 50 5 583-589
18. 478028 Glucagon-like peptide-1: A major regulator of pancreatic β-cell function. Perfetti R, Merkel P Eur J Endocrinol 2000 143 6 717-725
19. 478031 The entero-insular axis in type 2 diabetes - Incretins as therapeutic agents. Creutzfeldt W Exp Clin Endocrinol Diabetes 2001 109 Suppl 2 S288-S303
20. 479418 ConjuChem resumes DAC:GLP-1 clinical program, provides updates. ConjuChem Inc Press Release 2003 February 20
21. 482594 ConjuChem's DAC:GLP-1 clinical program advances. ConjuChem Inc Press Release 2003 March 19
22. 488830 ConjuChem starts US trial for DAC(TM):GLP-1. ConjuChem Inc Press Release 2003 May 08
23. 492844 CJC-1131, a long acting GLP-1 derivative, exhibits an extended pharmacokinetic profile in healthy human volunteers. Lawrence B, Dreyfus JF, Wen S, Guivarc'h PH, Drucker DJ, Castaigne J-P Diabetes 2003 52 Suppl 6 Abs 543-P
24. 493231 ConjuChem reports positive preliminary DAC:GLP-1 results. ConjuChem Inc Press Release 2003 June 11
25. 498249 Development and characterization of a glucagon-like peptide 1-albumin conjugate: The ability to activate the glucagon-like peptide 1 receptor in vivo. Jung-Guk K, Baggio LL, Bridon DP, Castaigne J-P, Robitaille MF, Jette L, Benquet C, Drucker DJ Diabetes 2003 52 3 751-759
26. 498254 CJC-1131, a long-acting GLP-1 analogue, is well tolerated in rats up to 14 days. Lawrence B, Wen S, Dunn D, Iordanova V, Castaigne J Toxicol Sci 2003 72 S-1 49
27. 498254 CJC-1131, a long-acting GLP-1 analogue, exhibits safety and tolerability in dogs. Wen S, Wilson S, Trebec D, Pham K, Castaigne J, Lawrence B Toxicol Sci 2003 72 S-1 48
28. 502385 ConjuChem's strong clinical results hit primary endpoints in type 2 diabetes trials. ConjuChem Inc Press Release 2003 August 21
29. 502385 ConjuChem's strong clinical results hit primary endpoints in type 2 diabetes trials. ConjuChem Inc Press Release 2003 August 21
30. 505939 Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Mentlein R, Gallwitz B, Schmidt WE Eur J Biochem 1993 214 3 829-835
31. 506488 Analyst evaluation of ConjuChem Inc. Dlouhy Merchant Group 2003 September 15 1-6